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Objective. To investigate the presence and persistence of human papillomavirus (HPV) infection in the oral mucosa of
patients with head and neck squamous cell carcinoma (HNSCC), and its correlation with prognosis.
Study design. HPV infection was characterized in tumors and pre and posttreatment oral scrapings in 51 patients with HNSCC
and matched controls using the SPF10 LiPA Extra assay. p16INK4A immunostain and in situ hybridization for high-risk HPV
genotypes recognized transcriptionally active infection in tumor samples. The risk of infection was compared in patients and
controls. The association of pretreatment HPV status with recurrence and survival and with posttreatment HPV persistence
was assessed.
Results. Oral HPV infection risk was significantly higher in patients with HNSCC than in controls (P < .001). Oral HPV
infection was associated with infection in the first posttreatment scrapings (P ¼ .015), but did not affect recurrence
or prognosis.
Conclusion. Oral HPV infection is frequent in patients with HNSCC and has no prognostic implications, suggesting that
posttreatment polymerase chain reaction monitoring on oral cells is not effective to monitor patient recurrence risk.
(Oral Surg Oral Med Oral Pathol Oral Radiol 2013;116:474-484)The human papillomavirus (HPV) is involved in the
genesis of tumors of the upper digestive tract, particu-
larly of squamous cell carcinomas (SCCs) arising in
the tonsils and the oropharyngeal region.1,2 Despite
changes in behavioral exposure to traditional risk
factors for head and neck SCC (HNSCC),3 the world-
wide incidence of oropharyngeal SCC has steadily
increased over recent years, which has been attributed
largely to the increasing number of HPV-associated
tumors.4 The identiﬁcation of HPV in oropharyngeal
carcinomas has prognostic signiﬁcance, with longer
survival and higher rate of response to therapy in cases
positive for HPV.5-7
The natural history of HPV infection has been
extensively detailed in the uterine cervix,8,9 whereas
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474infection and oncogenesis in the head and neck. In the
female genital tract, HPV persistence in the cervical
mucosa is the strongest risk factor for high-grade
intraepithelial and invasive SCC,10,11 and increases the
risk of tumor recurrence.12,13 HPV infection and
persistence is easily monitored on cervical exfoliated
cells, which can be used for the molecular identiﬁcation
and typing of HPV.14,15 It has been suggested that oral
exfoliated cells could be similarly used to monitor HPV
infection in the oral cavity and the risk of oropharyn-
geal SCC.16 Several authors17-20 reported that HPV
infection is more common in oral mucosa cells of
patients with HNSCC as compared with controls,
although scarce information is available on the persis-
tence of viral infection after tumor treatment21 and on
its correlation with tumor recurrence.22
Deﬁning the role of HPV infection in head and
neck cancerogenesis is further complicated by a wide
range of analytical methods available for virus detec-
tion, each with different sensitivity and speciﬁcity and
different targets. In particular, when compared with the
gold standard of viral oncogene transcription,23 widelyStatement of Clinical Relevance
The study sustains the hypothesis that incidental oral
human papillomavirus infection and persistence are
frequently observed in head and neck carcinoma and
bear no prognostic implications, whereas oncogenic
infection is rare and limited to a subset of oropha-
ryngeal cancers.
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methods are not sufﬁciently speciﬁc, while p16INK4A
(p16) immunostain and in situ hybridization (ISH) have
low sensitivity.23 Determination of p16 expression and
ISH are nonetheless currently the methods of choice in
most laboratories to identify HPV-associated oropha-
ryngeal SCC,20,21,23 but cannot easily be applied to oral
cytology monitoring, where HPV DNA ampliﬁcation
is the most convenient method to assess the presence of
the virus.20,21
We have recently demonstrated with a highly sensitive
commercial PCR and reverse hybridization-based assay
the presence of several low-risk (LR) and high-risk (HR)
HPV genotypes in over 90% of paired HNSCC biopsies
and oral mucosa samples, with an excellent agreement
for HPV infection and genotype characterization
between cancer and cytologic samples.24 In the present
study, we investigated the persistence of HPV infections
in the oral cavity of patients with HPV-positive and
HPV-negative HNSCC after cancer treatment by means
of repeated oral mucosa scrapings during patient follow-
up, to shed light on the natural history of HPV infection
in the upper digestive tract and on its correlation with
disease recurrence and survival.
MATERIALS AND METHODS
Patients and sampling
The study series consists of 51 consecutive patients
presenting to our center between 2008 and 2011, who
underwent an endoscopic biopsy for SCC of the mouth,
tongue, oropharynx, larynx, or hypopharynx. Only
patients with biopsy and cytologic samples adequate for
the study were included.24 The mean age of patients
was 62.2 (standard deviation, SD 11.5) years and the
male to female ratio was 43:8 (Table I). Inclusion
criteria were the ﬁrst presentation of a previously
untreated invasive SCC, and intention to referring to
our center for further therapy and follow-up. After
biopsy, 23 (45%) patients were treated with surgery
alone, 5 (9.8%) only with radiotherapy, 4 (7.8%),
4 (7.8%), and 1 (1.9%), respectively, with chemo and
radiotherapy, surgery and radiotherapy, and surgery and
chemotherapy, and 14 (27.4%) patients with surgery
followed by chemo and radiotherapy (Table I). Biopsy
samples were ﬁxed in formalin and processed routinely
for histopathologic study. The ﬁrst cytologic sample
(t0) was obtained from each patient 3-8 days after
endoscopy via a gentle scraping of the mucosa of the
cheeks with a plastic spatula. Follow-up cytologic
samples were obtained in the same way during planned
control visits to the outpatient clinic at 6 and 12 months
after hospital discharge, and at any subsequent control
visit until June 2012. Posttreatment scrapings were
classiﬁed as t1-t5 according to the number of scrapings
obtained from each patient. The scraped cells weresuspended immediately in ThinPrep-Preserv-Cyt solu-
tion (Cytec Corporation, Marlborough, MA) and stored
at 4 C. All follow-up biopsies performed in the head
and neck region and metastatic sites from the enrolled
patients were included in the study. The negative
control group consisted of patients who were seen at the
otolaryngology clinic for benign conditions and who
agreed to a buccal scrape. For each enrolled patient, 1
control was chosen after matching by age (within 5-
year categories) and sex among the control group. The
mean age of the control subjects was 61.6 (SD 11.1)
years. The protocol was reviewed and approved by the
Institutional Ethical Review Board and is in compliance
with the Helsinki Declaration. Each subject enrolled in
the project signed a detailed informed consent form.HPV DNA detection and typing
DNA extraction from buccal scrapes was performed
within 1 week of sampling by lysis and digestion with
proteinase K. Brieﬂy, pelleted cells from 1.5 mL of
Preserv-Cyt solution were washed in phosphate buff-
ered saline (PBS) and resuspended in 100 mL of lysis
solution (KCL 50 mM, TriseHCl 10 mM (pH 8.3),
MgCl 2 2.5 mM, Tween 20 0.45%, NP40 0.45%,
proteinase K 500 mg/mL) at 56 C for 1 h. Following
heat inactivation of proteinase K, 10 mL of the solution
was used for PCR ampliﬁcation of the HPV sequences
from the L1 region using SPF10 primers in a ﬁnal
reaction volume of 50 mL for 40 cycles.
For DNA isolation from the formalin-ﬁxed parafﬁn-
embedded biopsies, 3-5 10-mm-thick sections were
incubated in 200 mL of lysis solution (1 mg/mL
proteinase K in Tris 50 mM, pH 8.0, ethyl-
enediaminetetraacetic acid (EDTA) 1 mM, Tween 20
0.45%, and octylphenoxypolyethoxyethanol (IGEPAL)
CA-630 0.45%) for 16-24 h at 56 C. Proteinase K was
inactivated with heat and the lysates were centrifuged to
eliminate wax, puriﬁed with spin columns (Quiagen,
Crawley, UK), and resuspended in 100 mL of TRIS-
EDTA 0.1%. Ten microliters of the solution were used
for the reaction. Positive and negative controls were
introduced in each set of 12 reactions; these included
DNA from SiHa and HeLa cell lines at a speciﬁed
number of HPV copies and blank reagents throughout
all steps of the procedure. Concurrent ampliﬁcation of
human HLA-DPB1 gene was included in the assay as an
internal control for DNA adequacy. HPV type-speciﬁc
sequences were detected by the line probe INNO-LiPA
HPV genotyping assay version Extra (Innogenetics
NV, Ghent, Belgium) according to the manufacturer’s
instructions. The Extra version of the assay allows the
simultaneous and separate detection of 18 HR (16, 18,
26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73,
and 82), 7 LR (6, 11, 40, 43, 44, 54, and 70), and
Table I. Demographic characteristics, tobacco and alcohol consumption, tumor characteristics, and HPV genotype
distribution among patients with SCC and controls
Explanatory variable With FU Without FU Total Controls
No. 34 17 51 51
Sex (M/F) 28/6 15/2 43/8 43/8
Age e mean (SD) 67.1 (11.5) 59.9 (10.9) 62.3 (11.5) 61.6 (11.1)
Tumor site e n (%) N/A
Oral cavity 5 (14.7) 0 5 (9.8)
Tongue 6 (17.6) 2 (11.7) 8 (15.6)
Oropharynx 8 (23.5) 1 (5.8) 9 (17.6)
Larynx 10 (29.4) 11 (64.7) 21 (41.1)
Hypopharynx 4 (11.7) 3 (17.6) 7 (13.7)
Lymph node metastasis 1 (2.9) 0 1 (1.9)
Clinical stage e n (%) N/A
I 9 (26.4) 6 (35.2) 15 (29.4)
II 7 (20.5) 1 (5.8) 8 (15.6)
III 5 (14.7) 2 (11.7) 7 (13.7)
IV 13 (38.2) 8 (47) 21 (41.1)
Current smoker e n (%) 24 (70.5) 11 (64.7) 35 (68.6) 27 (52.9)
Alcohol abuse* e n (%) 5 (14.7) 6 (35.2) 11 (21.5) 0
Therapy e n (%) N/A
Surgery 16 (47) 7 (41.1) 23 (45)
Radiotherapy 2 (5.8) 3 (17.6) 5 (9.8)
Chemo and radiotherapy 4 (11.7) 0 4 (7.8)
Surgery and radiotherapy 1 (2.9) 3 (17.6) 4 (7.8)
Surgery and chemotherapy 0 1 (5.8) 1 (1.9)
Surgery, chemotherapy,
and radiotherapy
11 (32.3) 3 (17.6) 14 (27.4)
Tumor progression or
recurrence e n (%)
11 (32.3) 6 (35.2) 17 (33.3) N/A
HPV positive in t0 scraping e
n (%)
29 (85.2) 16 (94.1) 45 (88.2) 8 (15.6)
Genotype distribution in T0
scraping e n (%)
NT 7 (20.5) 1 (5.8) 8 (15.6) 7 (13.7)
LR 6 (17.6) 4 (23.5) 10 (19.6) 0
HR 16 (47) 11 (64.7) 27 (52.9) 1 (1.9)
FU, follow-up; NT, no speciﬁc type; LR, low risk; HR, high risk; N/A, not applicable.
*Consumption of 15 drinks per week.
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patterns were analyzed with the speciﬁc software Line
reader andAnalysis Software (LiRAS) forLiPAHPVand
the results were conﬁrmed by 2 independent readers.25HPV DNA in situ hybridization
DNA ISH was performed on parafﬁn tissue sections
with the INFORM HPV III family 16 and INFORM
HPV II family 6 probes (Ventana Medical Systems Inc,
Tucson, AZ) using the ISH I View Blue Plus Detection
Kit according to the manufacturer’s instructions, on
a Ventana BenchMark XT automated stainer. The
probes hybridize, respectively, with HR HPV geno-
types 16, 18, 33, 35, 45, 51, 52, 56, and 66 and with LR
genotypes 6 and 11. Cases were read by the study head
and neck pathologist (P.M.). Any deﬁnitive nuclear
staining in the tumor cells was considered positive.
Cases were classiﬁed in a binary manner as either
positive or negative.p16 Immunostain
For the immunohistochemical detection of p16 protein,
the CINtec Histology Kit (MTM Laboratories AG,
Heidelberg, Germany) was used according to the
manufacturer’s instructions. Samples of high-grade
cervical intraepithelial lesions were used as positive
controls. Cases were read by the study head and neck
pathologist (P.M.). Brown staining of tumor cell nuclei
and cytoplasm was interpreted as positive. Cases with
p16 immunostain that showed intense diffuse, contin-
uous, and conﬂuent nuclear and cytoplasmic staining of
tumor cells were considered as positive according to
previously published criteria.26Statistical analysis
The ShapiroeWilk test was used to test the normal
distribution of quantitative variables. When quantita-
tive variables were normally distributed, the results
were expressed as mean values and SD, otherwise
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percentile) were reported; comparisons between
groups were performed with the appropriate parametric
or nonparametric tests. Qualitative variables were
summarized as counts and percentages, and patient
groups were compared using c2 test or Fisher’s exact
test, as appropriate.
Logistic regression models were used to ﬁnd the
odds of HPV infection among controls and patients.
Results were expressed as odds ratio (OR, crude or
adjusted for age, sex, smoke, and alcohol) with 95%
conﬁdence interval (CI). Disease-speciﬁc survival
(DSS) and disease-free survival (DFS) were derived
with the use of the KaplaneMeier product-limit method
and the log-rank test was used to analyze comparisons
among groups. Univariate and multivariate Cox pro-
portional hazard models were ﬁtted to investigate the
associations between DSS and DFS and covariates.
Results were expressed as hazard ratios (HRs) with
95% CI. All tests were 2 sided. Data were analyzed
with the STATA statistical package (release 10.0, 2009,
Stata Corporation, College Station, TX).RESULTS
t0 Cytologic samples
HPV DNA was present in 45 cytologic samples
(88.2%). Twenty-seven (52.9%) of them hosted 1 or
more HR HPV genotypes (range 1-5), 10 (17.8%)
hosted only LR genotypes, and in 8 (15.6%) no speciﬁc
viral type could be identiﬁed. In the control population,
1 (1.9%) sample was positive for HR HPV, and in 7
(13.7%) no speciﬁc viral type could be identiﬁed. Case
and control series signiﬁcantly differed in the propor-
tion of cases positive for HPV and HR HPV, and in the
distribution of LR, HR, and nonetype-speciﬁc infec-
tions (P < .001) (Table I).Tumor biopsy samples
SPF10 LiPA assays of 46 (90.1%) tumor biopsies were
positive for HPV DNA. Twenty-seven (52.9%) of them
hosted 1 or more HR HPV genotypes, 11 (21.5%)
hosted only LR genotypes, and in 8 (15.6%) no speciﬁc
viral type could be identiﬁed. HPV was present in all
SCCs of the mouth and of the hypopharynx (5 and 7,
respectively), in 18 (85.7%) of 21 SCCs of the larynx,
in 7 (87.5%) of 8 SCCs of the tongue, in 8 (88.8%) of 9
SCCs of the oropharynx, and in the lymph node
metastasis. HR genotypes were present in 2 (40%)
SCCs of the mouth, in 5 (71.4%) SCCs of the hypo-
pharynx, in 12 (57.1%) SCCs of the larynx, in 3
(37.5%) SCCs of the tongue, and in 5 (62.5%) SCCs of
the oropharynx. The immunohistochemical stains
showed that p16 was expressed in at least 75% of the
neoplastic cells in 4 SCCs (2 from the oropharynx,1 from the larynx, and 1 from the tongue), all positive
for HPV DNA (Figure 1). ISH documented the pres-
ence of integrated and episomal HR HPV in the nuclei
of the 2 p16-positive oropharyngeal tumors, whereas all
other samples and ISH for LR HPV were negative
(Figure 1). Fisher’s exact test showed a signiﬁcant
correlation between p16 and ISH results (P ¼ .004). No
correlation was observed between the presence of HPV
and HR HPV DNA in biopsies and p16 expression or
ISH results.Comparison of HPV status in t0 scrapings and
tumor biopsy samples
In 38 (74.5%) patients there was complete agreement
for type-speciﬁc infections and infection proﬁle or
absence of infection between t0 scrapings and tumor
biopsy samples. In 8 (15.6%) cases, biopsy and cyto-
logic samples shared 1 or more HR genotypes, but
differed for further type-speciﬁc infections: in 4 cases,
1 genotype (2 HR and 2 LR) was only present in the
biopsy; in 3 cases, 1 genotype (2 HR and 1 LR) was
only present in the scraping; in the last case, 1 HR and
1 LR genotypes were only present, respectively, in
the biopsy and in the scraping. In 5 patients no corre-
lation was found between biopsy and scraping. In 2 of
them, only the biopsy result was positive (1 HR, 1
nonetype-speciﬁc infection); in 1, only the scraping
was positive for a nonetype-speciﬁc HPV infection;
in 1, the biopsy result showed LR infection, and the
scraping nonetype-speciﬁc HPV DNA; in the last, the
biopsy result showed a nonetype-speciﬁc infection,
and the scraping an HR genotype.Follow-up cytologic samples
Thirty-four (66.6%) patients had 1 or more scrapings
(range 1-5, mean 2.0, SD 1.1) performed during the
follow-up. Four patients did not enter the follow-up
program and died of progressive disease 7-8 months
after the diagnosis. Three of them were positive for HR
HPV in both tumor and scraping, the last one had LR
HPV in both samples. Thirteen patients chose to refer to
a different outpatient clinic. There was no difference
in HPV status (P ¼ .650), HR HPV status (P ¼ .372),
and genotype distribution (P ¼ .426) in t0 scrapings
obtained from patients with and without follow-up.
These 2 groups of patients did not differ in age, sex,
smoking habit, stage, and tumor site distribution
(Table I). The number of patients that fulﬁlled each
follow-up scraping, the proportion of cases for positive
HPV, and the genotype distribution in the follow-up
cytologic samples are detailed in Table II. HPV status,
HR HPV status, and genotype distribution in scrapings
obtained at each follow-up point were signiﬁcantly
different (P < .001) from the control series, whereas
Fig. 1. Photomicrographs showing p16INK4A diffuse immunoreactivity (A) and HR HPV ISH nuclear dot-like signal (B) in an
HPV-associated nonkeratinizing oropharyngeal SCC, and the absence of p16 expression (C) and of ISH signal (D) in a keratinizing
SCC of the tongue (A, C: diaminobenzidine tetrahydrochloride chromogen and hematoxylin nuclear counterstain; B, D: nitro-blue
tetrazolium/5-bromo-4-chloro-30-indolyphosphate chromogen and red counterstain II; magniﬁcation: A, C 10; B, D 20).
Table II. Number of patients, timing, and HPV distribution in baseline and follow-up oral scrapings from patients
and controls
Explanatory variable t0 t1 t2 t3 t4 t5 Controls
No. of patients 51 34 21 11 4 1 51
Median (IQR) time from
diagnosis
// 9 (6-12) 19.5 (15-24) 27 (27-30) 36 (31-39) 33 (e) //
HPV DNA (%) 46 (90.1)* 29 (85.2)* 17 (80.9)* 9 (81.1)* 3 (75.0) 1 (100) 8 (15.6)
HR HPV (%) 27 (52.9)* 16 (47.0)* 8 (38.0)* 7 (63.6)* 2 (50.0) 0 1 (1.9)
LR HPV (%) 10 (19.6)* 9 (26.4)* 5 (23.8)* 0 0 0 0
NT HPV (%) 9 (17.6)* 4 (11.7)* 4 (19.0)* 2 (18.1) 25 (50.0) 1 (100) 7 (13.7)
IQR, interquartile range; HPV, human papillomavirus; HR, high risk; LR, low risk; NT, no speciﬁc type.
*Signiﬁcantly different from controls (P < .001).
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groups for these parameters.
Natural history of type-specific HPV infections
Three (8.8%) patients tested negative for HPV in all
posttreatment scraping samples. One of them had
nonetype-speciﬁc HPV DNA in the tumor sample, the
others had negative biopsy results. Sixty-seven indi-
vidual type-speciﬁc infections, deﬁned as the presence
of a speciﬁc viral type in 1 or more consecutive
samples, and 12 infections not sustained by a speciﬁc
viral type were identiﬁed in the other 31 patients and
are listed in Table III. Brieﬂy, 25 persistent type-
speciﬁc infections (17 HR, 68% and 8 LR, 32%),
deﬁned as the presence of a speciﬁc HPV type in at
least 2 consecutive samples,11 were present since t0
in 18 patients. All but one (96%) were observed alsoin the patient biopsy sample; the only discordant case
was a persistent HR oral infection whose tumor bio-
psy result was positive for nonetype-speciﬁc HPV
DNA. The mean duration of observed infections was
15.8 months (6-42, SD 8.4). Twelve HR and 7 LR
infections (76%) persisted in all follow-up scrapings.
Remission was observed in 5 HR and 1 LR infection
after 12-19 months (mean 13.8, SD 4.1), but could not
be documented for the 19 infections that persisted until
the last follow-up scraping. Four HR infections recurred
after remission. In 7 patients, 12 (8 HR, 75% and 4 LR,
25%) type-speciﬁc infections were present at t0 but
were not found in the next follow-up scrapings. Ten
(83.3%) of these infections, including a coinfection
sustained by 5 different HR genotypes, were also
present in the tumor biopsy. One HR and 1 LR infec-
tion were not present in the biopsy, which however
Table III. Natural history of oral HPV infections during the follow-up of patients with HPV-positive SCC
Case FU (months)
No. of speciﬁc
infections
No. of persistent
infections since t0
(months of persistence)
No. of resolved
infections at t0
No. of infections
recurred during FU
No. of infections
appeared during FU
(months of persistence)
HR LR NT HR LR NT HR LR NT HR LR NT HR LR NT
1 6 1 1 (6)
2 9 1 1* (9)
3 42 2 2 1* (42) 1 2y
4 12 1 1*
5 9 1 1 1* 1
6 15 1 1 1* (9) 1
7 9 4 2* (9) 1 1
8 24 3 2 1* (24) 1 1 1,1 (12)
9 33 1 2 1* 1 1
10 21 2 1 2* (9,21) 1* (21)
11 27 2 3 1* (12) 1* 1 2y
12 24 1 1* (24)
13 18 1 2 1* 1 1
14 38 1 1 (26)
15 42 2 2 1* (12) 1* (12) 1 1 (24)
16 12 2 2* (12)
17 30 1 1 1* (30) 1
18 27 2 1* 1
19 6 1 1 1* (6) 1* (6)
20 12 1 1* (12)
21 36 2 3 2* 1 2 (12)y
22 27 5 1 5* 1
23 36 7 2* (19,19) 2 2,1 (30)
24 9 1 1* (9)
25 15 1 1* (15)
26 15 1 1 1* (6) 1
27 15 1 1* (15)
28 18 1 1 1 1*
29 12 1 1* (12)
30 24 1 2 1* 1 1
31 6 1 1 (6)
FU, follow-up; HR, high risk; LR, low risk; NT, no speciﬁc type.
*The same type-speciﬁc infection was present in tumor biopsy.
yThe same viral type was present in 2 nonconsecutive scrapings.
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infections. Three infections (1 HR and 2 LR) recurred
in later nonconsecutive scrapings. Twenty-three (13 HR
and 10 LR) type-speciﬁc de novo infections were
observed in follow-up scrapings from 16 patients. In 3
cases, the same viral type was responsible for 2
different infection episodes in nonconsecutive scrapings
from the same patient. Two (1 HR and 1 LR) (8.6%) of
these 23 type-speciﬁc infections had been present in the
tumor biopsy but not in the t0 scraping. Eleven were
observed in the last available scraping from the patient;
of the other 12, 4 persisted and were documented in
consecutive scrapings. Globally, 37 (55.2%) of 67
individual infections were present at t0; 11 (29.7%) of
them underwent permanent remission, 19 (51.3%)
persisted, and 7 (18.9%) recurred after remission.
Thirty infections (44.7%) were contracted during the
follow-up (7 recurrent and 23 new infections).
In 7 patients, nonetype-speciﬁc HPV infections were
observed at t0. In 5 patients, all with nonetype-speciﬁcHPV DNA in the tumor biopsy, a consecutive series of
scrapings positive for nonetype-speciﬁc infections
(mean follow-up 21 months, SD 7.6, range 15-33) was
interrupted by a single type-speciﬁc (2 HR and 3 LR)
infection. In 1 case, the nonetype-speciﬁc viral infec-
tion persisted throughout the entire follow-up (6
months), but the biopsy result was negative for HPV; in
the last patient, the results of both tumor biopsy and t1
scraping were positive for LR HPV infection. Two
nonetype-speciﬁc infections were acquired de novo
during the follow-up; one, presenting in a previously
negative patient, persisted for 24 months, the other
appeared in the last follow-up scraping of a patient who
hosted 5 different HR type-speciﬁc infections in the
biopsy and t0 scraping, all resolved in the next
scraping.
Correlation between tumor and oral HPV infection
The odds of an oral HPV or HR HPV infection at the
time of diagnosis were compared among patients and
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controls to have any oral HPV infection (OR adjusted
for sex, age, smoke, alcohol 87.38, 95% CI 15.81-
483.02, P < .001) or HR HPV infection (adjusted OR
79.54, 95% CI 8.44-749.60, P < .001). Fisher’s exact
test showed a signiﬁcant association of HPV status
between tumors and t0 scrapings; no association was
observed with scrapings obtained at t1, t2, and t3.
Tumor HR HPV status was signiﬁcantly associated
with t0 and t1 scrapings. A signiﬁcant association was
observed for HPV and HR HPV status also between t0
and t1 but not t2 or t3, and between t1 and t2 but not t3
scrapings (Table IV).HPV infection in follow-up biopsy samples
Sixteen posttreatment biopsies were obtained from 15
patients, all with previous HPV-positive cytologic
samples. Biopsies included 7 local recurrences, 1 second
tumor, 2 lymph nodes, and 1 pulmonary metastasis, and
5 non-neoplastic tissue samples from the site of the
treated primary tumor. The mean time from the initial
diagnosis was 10.2 months (SD 13.8, range 1-33) for the
non-neoplastic samples, 3 of which were obtained after
surgical treatment and 1 after radiotherapy, 20.8 months
(SD 12.1, range 9-38) for local recurrences, which
occurred in 3 cases after surgery and chemo-
radiotherapy, in 2 after chemoradiotherapy, and in 2
after surgery alone, 11 months for the second tumor,
presenting after chemoradiotherapy, 16 and 24 months
for the lymph node metastases, both occurring after
surgery, and 26 months for the pulmonary metastasis,
which presented in a patient treated with surgery and
chemoradiotherapy. HPV DNA was found in all biop-
sies, independently of their site, time interval, type of
treatment, and diagnosis (negative, tumor, or metas-
tasis). The same type-speciﬁc infections observed in the
temporally closest scraping were present in all samples;
in 4 of them, 1 further viral type not observed in the
scraping was present in the biopsy, and in 1 case 1 of
the viral types present in the scraping was absent in the
biopsy. None of the posttreatment biopsies were positive
by p16 or ISH.Clinical follow-up
Median follow-up time was 28 months (IQR 19-42,
range 6-51). Thirteen patients had 1 or more local
recurrences (n ¼ 7), a second SCC in the upper aero-
digestive tract (n ¼ 1), metastasis to the laterocervical
lymph nodes (n ¼ 3), and lung metastasis (n ¼ 2), at
a median time of 17 months (IQR 9-23, range 3-36)
after the initial diagnosis and response to therapy. At
12, 24, and 36 months the rate of patients free from
disease was 87.0% (95% CI 73.3-93.2), 76.6% (95% CI
60.6-86.7), 65.6% (95% CI 47.0-79.1), respectively;DFS ranged from 3 to 51 months (median 26, IQR
15-40). Eleven (19.6%) patients died. Four of them did
not respond to treatment or died of surgical complica-
tions: 2 patients of 52 and 79 years with stage IV
tumors suffered disease progression despite surgery and
adjuvant chemo and radiotherapy, 1 (73 years old, with
stage IV tumor) died of surgery-related complications,
and 1 (77 years old, stage II) did not respond to
radiotherapy, while surgery and chemotherapy had
been excluded for severe concomitant diseases. Six
other patients died of their disease, including 4 with
disease recurrence, 1 with lung metastasis, and 1 with
laterocervical metastasis. One patient died of myocar-
dial infarction with no evidence of tumor. One patient
with a second tumor, 1 with recurrent tumor, 1 with
lung metastasis, and 1 with laterocervical metastasis
were alive with disease at the time of the last follow-up;
2 local recurrences and 1 laterocervical metastasis were
successfully treated with surgery. At 12, 24, and 36
months the rate of patients who were alive was 92.0%
(95% CI 80.1-96.9), 85.2% (95% CI 71.3-92.7), 73.1%
(95% CI 56.0-84.4), respectively. None of the controls,
including the 1 with HR HPV infection, were diagnosed
with HNSCC at our center after enrollment in the
control group.
Correlation of HPV infection with outcome
and survival
HPV DNA was present in the biopsies and in oral
scrapings of 15 (88.2%) of 17 patients who suffered
disease progression, recurrences, second tumors, or
metastases, and in 30 (88.2%) of 34 patients who did
not. Eleven (64.7%) and 16 (47%) infections, respec-
tively, were sustained by HR HPV in the biopsies; 10
(58.8%) and 14 (41.1%) in the cytologic samples. HPV
was present in the tumors and in oral scrapings of all 11
patients with unfavorable outcome (8 HR in both types
of sample) and of all 4 patients who were alive with
disease (3 HR in the biopsies and 2 in the scrapings); of
the 36 patients with favorable outcome, 31 (86.1%) had
HPV-positive tumors and 32 (88.8%) had HPV-positive
scrapings; HR genotypes were present in 16 (44.4%)
tumors and in 17 (47.2%) cytologic samples. Twenty-
eight patients were treated with protocols including
chemo and/or radiotherapy: HPV and HR HPV infec-
tions were present, respectively, in 12 (92.6%) and 9
(63.2%) tumors of the 13 patients of this group that
experienced disease recurrence or progression, and in
13 (86.6%) and 6 (40%) tumors of the 15 patients that
did not (P > .05). Oral HPV infection was present in 11
(84.6%) patients with recurrence or progression and in
12 (80%) patients without; HR genotypes were present
in 8 (66.6%) and 7 (46.6%) cases, respectively. In these
28 patients, HPV was present in the tumors and in the
oral cavity of all 7 patients with unfavorable outcome
Table IV. Concordance (%) and signiﬁcance levels (P) of Fisher’s exact tests for HPV and HR HPV infection of each
sample series compared with the following series
HPV biopsy HPV t0 HPV t1 HPV t2 HR HPV biopsy HR HPV t0 HR HPV t1 HR HPV t2
t0 91.2% (<0.001) 96.1% (<0.001)
t1 85.3% (0.094) 88.2% (0.015) 70.6% (0.037) 70.6% (0.037)
t2 85.7% (0.080) 85.7% (0.080) 90.5% (0.012) 66.7% (0.203) 61.9% (0.038) 76.2% (0.032)
t3 90.9% (0.182) 100% (0.182) 72.7% (0.491) 72.7% (0.491) 81.8% (0.088) 81.8% (0.088) 72.7% (0.242) 63.6% (0.545)
HPV, human papillomavirus; HR, high risk.
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were alive with disease, 4 had HPV-positive tumors (all
HR) and 3 had HPV-positive oral scrapings (2 HR); of
the 17 patients with favorable outcome, 14 (82.3%) had
HPV-positive tumors and 13 (76.4%) HPV-positive
scrapings; HR genotypes were present, respectively, in
7 (41.1%) and in 8 (47%) samples. Fisher’s exact test
did not show a signiﬁcant association of HPV and HR
HPV infection and outcome in all evaluated groups
(P > .05).
The Cox proportional hazard analysis did not show
any correlation between DFS or DSS and the presence
of HPV or HR HPV infection in tumor or oral mucosa
cells at t0. Only clinical stage IV was signiﬁcantly
correlated with shorter DSS and DFS (Figure 2). In
patients with cytologic follow-up, Fisher’s exact test
did not show any association between HPV or HR HPV
infection at t1, t2, and t3 and tumor recurrence.
DISCUSSION
The present study reports that oral HPV infections at
the time of tumor diagnosis and their persistence during
the ﬁrst months of follow-up are signiﬁcantly more
frequent in subjects with HPV-positive SCC than with
HPV-negative SCC, and that the risk of hosting HPV in
the oral mucosa is signiﬁcantly higher in subjects with
head and neck carcinomas than in controls. The high
prevalence of oral HPV infection that we observed in
HNSCC as compared with the general population
suggests that the presence of the tumor might favor the
localization and persistence of the virus in the tumor
cells27,28 and in adjacent mucosa,17,20 possibly medi-
ated by immune suppressive mechanisms. It has
recently been shown that SCCs activate several strate-
gies in order to evade the host immune response,29
which could favor viral infection and persistence in
both tumor and oral mucosa. An increased risk of HPV
oral infection because of immunologic dysfunction has
indeed been documented in patients positive for
HIV,30,31 and in non-HIV tobacco smokers.32,33
Detecting HR HPV DNA in tumor tissue, while sup-
porting an association between virus and cancer, does not
distinguish whether HPV is transcriptionally active and
thus able to promote carcinogenesis (the so-called driver
infection), or inactive, probably representing incidental orpassenger infection. To determine the oncogenic activity
of HPV, direct or indirect methods that assess viral
integration or viral oncogene transcription are neces-
sary.23 In the present study, an oncogenic HR HPV
infection was demonstrated by means of validated p16
immunostain and ISH in only 2 oropharyngeal SCCs,
which is the site where HPV carcinogenesis has been
most consistently documented,1,2 whereas most of the
infections recorded in tumors by PCR did not show
evidence of viral integration or transcription. The mark-
edly different rates of HPV positivity that we obtained
with PCR and ISH in our tumor series likely depend on
the different analytical sensitivities of the 2 tests: SPF10
LiPA has the highest sensitivity among HPV typing
assays, because of the short ampliﬁed DNA fragment (65
base pairs).34 SPF10 LiPA sensitivity differs for different
HPV genotypes, but is at least 1-10 copies per 103 cells,35
whereas the ISH estimated sensitivity threshold is 1-2
viral copies per cell.36 We assume that, in PCR-positive
and ISH-negative tissue samples from the present series,
the viral load was lower than this threshold, as observed
by Chaturvedi et al.37 who documented with quantitative
(q)PCR that 22.5% and 50%, respectively, of SPF10
LiPA HPV16- and HPV none16-positive tumors had
less than 1 viral genome per cell. The fact that HPV
transcriptional activity has been associated with a viral
load of at least 0.5 copies per cell38,39 supports the
hypothesis that PCR-positive p16- and/or ISH-negative
infections observed in the present study carry no onco-
genic activity. However, on the basis of previous litera-
ture data40-43 we cannot deﬁnitely exclude oncogene
transcription in these infections. A conclusive clariﬁca-
tion of this aspect would require the ampliﬁcation of HPV
E6/E7 messenger RNA, which could not be performed in
our series because of the lack of frozen tumor samples.
Indirect evidence from prognostic and survival associa-
tions suggests that most infections identiﬁed in the
present study are passenger infections, as opposed to the
strong prognostic correlations recently reported for
oropharyngeal SCCs associated with HR HPV infec-
tion,5-7 we did not ﬁnd any differences in the rates of
disease progression or recurrence, nor in outcome or
survival of patients positive for HPV or HR HPV DNA.
No correlation was found even when we considered only
those patients who had been treated with protocols
Fig. 2. KaplaneMeier survival curves showing a signiﬁcant association between clinical stage IV and DSS; the presence of HPV
and HR HPV infections in tumor biopsies and in oral scrapings did not inﬂuence patient survival.
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more effective in HPV-associated tumors.7
Very few studies have so far addressed the issue of
HPV persistence in the oral mucosa after tumor treat-
ment. Recently, Agrawal et al.21 demonstrated that
posttreatment oral HPV infections were signiﬁcantly
more frequent among individuals diagnosed with
HPV16-positive HNSCC than with HPV16-negative
HNSCC, and that not only HPV16 but also other HR
and LR HPV types were more common in the oral
mucosa of patients with positive tumors. These obser-
vations are in agreement with ours regarding HPV
persistence in the oral cavity after tumor treatment.
We also documented that over two-thirds of the type-
speciﬁc oral infections present at diagnosis persisted
in the follow-up for at least 6 months, with a maximum
of 42 months. Moreover, several infections appearing
posttreatment were sustained by viral types responsible
for previously resolved infections, suggesting the
reactivation of a latent infection or re-infection from
a site of persistence. Interestingly, the strength of
association between tumor and oral positivity for HPV
and HR HPV progressively reduced with increasing
follow-up time. When we compared cytologic samplegroups, the strongest correlation was found between the
closest scraping series (t0 and t1, t1 and t2), suggesting
that the infection proﬁle changes over time, with both
resolutions and new infections.
We observed several persistent infections in which
a speciﬁc viral type could not be identiﬁed. In most of
these patients, a speciﬁc genotype was characterized
in a single follow-up sample. It is possible that the
nonetype-speciﬁc positive results were because of the
presence of a number of viral genomes lower than
the threshold of detection of the linear array, and that
the genotype was recognized only when the viral load
increased above this threshold (as a consequence of
active replication or of sampling issues). As an alter-
native hypothesis, it is recognized that consensus
primers amplifying the HPV L1 region (including
SPF10) may fail to identify fully integrated viruses,
yielding false-negative44 or nonetype-speciﬁc results
(Morbini et al., personal communication). This phe-
nomenon fully explains our observation of a persistent
HR HPV oral infection in a patient with nonetype-
speciﬁc viral DNA in the biopsy, and could be true for
the persistent nonetype-speciﬁc infections positive for
HR HPV in a single scraping. It seems, however,
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given that integration is not commonly observed in LR
HPV genotypes. Finally, SPF10 LiPA ampliﬁes but
does not recognize cutaneous HPV genotypes, which
have been previously found in the oral mucosa.45 The
eventual presence of a genital type-speciﬁc infection in
these patients renders this possibility unlikely. Quanti-
tative, genotype-speciﬁc PCR on cytologic samples will
help to clarify this aspect.
As far as prognosis is concerned, we could not ﬁnd
any association between HPV persistence in the oral
mucosa and tumor recurrence, as previously reported.22
On the contrary, patients with and without oral HPV
infection or persistence showed similar recurrence rates,
and all posttreatment biopsies including normal mucosa
from sites of previous tumors hosted the virus. The
prognostic relevance of oral infections, especially
persistent ones, is probably correlated with their onco-
genic potential. No direct assumption could be drawn on
the nature (passenger versus driver) of the oral infections
recorded with scrapings, since viral transcriptional
activity was not determined in oral cytologic samples.
However, all persistent infections documented in post-
treatment biopsies did not show transcriptional activity.
Literature data offer indirect evidence that oral infections
are probably passenger: qPCR studies reported a median
viral load of 13.0 HPV genomes per 103 oral exfoliated
cells in patients with oropharyngeal cancers,20 which
is lower than the loads associated, respectively, with
oncogene transcription,38,39 and with replicative infec-
tions in the cervical mucosa (50-100 copies per cell).9
The lack of prognostic implications for the presence
and persistence of HPV DNA in the oral mucosa
suggests that consensus PCR on oral scraping is not
effective for posttreatment monitoring, whereas its
results may bear severe psychosocial implications for
patients and families. As in tissue samples used for
cancer diagnosis, we need to establish parameters that
more accurately discriminate between passenger and
potentially oncogenic infections in the oral mucosa, to
make oral cytology an effective instrument for patient
screening and monitoring.46REFERENCES
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